2026-11-02 Product
Merck to Present New Oral HIV Portfolio Data at HIV Glasgow 2026 Phase 3 subgroup analyses and patient-reported outcomes of once-weekly oral ISL/LEN
D1 -0.8% · +5d +0.3%
2026-10-29 Earnings
Earnings report D1 +3.8% · +5d +0.4%
2026-10-29 8-K filing
8-K: Item 2.02, Item 9.01 D1 +3.8% · +5d +0.4%
2026-10-26 Product Bull
Merck's Sac-TMT Gets FDA Priority Review; Cuts Death Risk 32% in Endometrial Cancer FDA accepted BLA with priority review, PDUFA June 15, 2027; TroFuse-005 showed 32% lower death risk and 41% lower progression/death risk vs chemo
D1 -3.2% · +5d +5.5%
2026-10-23 → 10-26 Product
Merck-Moderna Melanoma Vaccine Data at ESMO26 Draws Cautiously Positive Reactions Oncology pipeline updates at ESMO26 include Sac-TMT and calderasib data
D1 -1.3% · +5d +2.9%
› 4 waves of this story2026-10-23 Data leaked ahead of ESMO 2026 Presidential Symposium; confirmed 42% reduction in disease recurrence2026-10-24 Formal data confirm key endpoints; CEO expects approval in 2027; analyst sees potential standard-of-care change2026-10-25 ESMO26 discussant gave positive but not overly enthusiastic take on INTerpath-001; approval path in focus2026-10-26 Oncology pipeline updates at ESMO26 include Sac-TMT and calderasib data2026-10-25 Capital Bear
Carolina Wealth Advisors Cut Merck Stake by 97.8% in Q3 Large institutional trim signals some investor caution on Merck's outlook
D1 -3.2% · +5d +5.5%
2026-10-22 → 10-23 Capital Bull
Brookstone Capital Management boosts Merck stake by 15.2% Institutional investor increased stake in Q3, signaling long-term confidence
D1 -1.8% · +5d -0.6%
› 2 waves of this story2026-10-22 Axxcess cut 44.1%, Diversify raised 32.5%, showing institutional divergence2026-10-23 Institutional investor increased stake in Q3, signaling long-term confidence2026-10-14 8-K filing
8-K: Item 5.02 D1 +3.8% · +5d +1.7%
2026-10-10 → 10-12 Product Bear
Jefferies Cuts Merck's Remigromig Peak Sales Forecast by 60% Detailed trial data raises efficacy and safety concerns, impacting the drug's commercial outlook
D1 -0.1% · +5d -1.3%
› 2 waves of this story2026-10-10 First presentation of one-year pivotal BRUNELLO results; addresses persistent DME need2026-10-12 Detailed trial data raises efficacy and safety concerns, impacting the drug's commercial outlook2026-10-07 → 10-08 Company
Merck, Moderna, Tempus expand personalized neoantigen therapy collaboration Moderna and Merck advance personalized cancer vaccine toward launch, each dose designed around patient's own tumor
D1 +0.6% · +5d +3.2%
› 2 waves of this story2026-10-07 Tempus to support commercialization of intismeran autogene with sequencing and sample logistics2026-10-08 Moderna and Merck advance personalized cancer vaccine toward launch, each dose designed around patient's own tumor2026-10-07 Regulation Bear
Dutch Court Bars Merck from Selling Subcutaneous Keytruda in 8 European Markets Court rules for Halozyme, restricting Merck's subcutaneous Keytruda sales in Europe
D1 +0.6% · +5d +3.2%
2026-09-29 → 10-01 Capital
Merck to Hold Q3 2026 Earnings Call on Oct 29 Company confirms Oct 29 Q3 release; consensus EPS $2.25, revenue $17.52B
D1 +0.4% · +5d -4.9%
› 2 waves of this story2026-09-29 $400M upfront expands precision oncology pipeline targeting common cancer mutation2026-10-01 Company confirms Oct 29 Q3 release; consensus EPS $2.25, revenue $17.52B2026-10-01 Product Bull
Merck's Tulisokibart Meets Primary Endpoint in Phase IIb HS Study High and medium doses showed superiority over placebo at week 16, supporting HS pipeline progress
D1 -1.0% · +5d -1.0%
2026-09-28 → 09-29 Capital
Merck's $2.13B Cancer Drug Licensing Deal with SciBrunch Adds $400M upfront and KRAS G12D inhibitor details; stock slips 1.5%
D1 -0.1% · +5d -6.2%
› 2 waves of this story2026-09-28 $400M upfront, boosts oncology pipeline, reflects US drugmakers' China licensing trend2026-09-29 Adds $400M upfront and KRAS G12D inhibitor details; stock slips 1.5%2026-09-25 → 09-28 Regulation Bull
FDA expands Merck's Welireg label for advanced kidney cancer, adding third indication FDA approval adds new indication, sales climb, wider use
D1 +0.5% · +5d -3.0%
› 2 waves of this story2026-09-25 FDA approval for belzutifan plus lenvatinib in previously treated advanced ccRCC, expanding oncology portfolio.2026-09-28 FDA approval adds new indication, sales climb, wider use2026-09-25 Product Bear
Merck Voluntarily Withdraws I-DXd BLA for ES-SCLC Voluntary withdrawal of BLA for ifinatamab deruxtecan in pretreated ES-SCLC, a setback for oncology pipeline.
D1 +0.5% · +5d -3.0%
2026-09-24 Product Bull
Merck's Remigromig Meets Primary Endpoint in Pivotal DME Trial BRUNELLO study met primary endpoint, offering potential new treatment for diabetic macular edema
D1 -0.1% · +5d -2.8%
2026-09-22 Product Bull
Merck's WINREVAIR FDA Label Update Includes HYPERION Data FDA approves label update for WINREVAIR, adding Phase 3 data in newly diagnosed PAH, boosting product position
D1 +0.9% · +5d -1.1%
2026-09-18 → 09-21 Product Bull
Merck's Keytruda+Padcev Gets CHMP Positive Opinion in EU CHMP backs combo as perioperative treatment for resectable MIBC
D1 -0.2% · +5d +1.3%
› 2 waves of this story2026-09-18 EU panel recommends approval for perioperative treatment of resectable MIBC2026-09-21 CHMP backs combo as perioperative treatment for resectable MIBC2026-09-21 Product Bull
Merck's Subcutaneous Keytruda Approved in Japan Japan approves KEYTRUDA QLEX SC for all approved Keytruda indications
D1 +1.8% · +5d -0.5%
2026-09-08 Product Bull
Merck's Keytruda-Moderna Combo Drives Stock Near 52-Week High Zacks cites positive Phase III data; Keytruda peak sales projected at $35B by 2028
D1 -1.2% · +5d -3.1%
2026-09-03 Company Bear
Merck's Keytruda Biosimilar Set to Enter US Market Cipla and Qilu partner to launch Keytruda biosimilar in US, potentially impacting Merck's key product
D1 +0.5% · +5d -5.5%
2026-08-26 Capital
MRK Hits 52-Week High; Institutional Moves Mixed (BlackRock Up, Beverly Hills Down) New high reflects market optimism on melanoma data and pipeline, but institutional actions diverge: Beverly Hills cut 59.7%, BlackRock added 0.5%
D1 -2.1% · +5d -1.0%
2026-08-20 Analyst
2 analyst rating changes (1 up / 1 down) D1 -2.1% · +5d +0.4%
2026-08-19 Other Bull
MRK Hits 52-Week High as Pharma Group Strengthens Multiple sources confirm MRK at 52-week high; pharma among strongest market groups
D1 +12.6% · +5d +0.6%
2026-08-04 → 08-13 Earnings Bull
Merck Q2 beat, raises guidance, analyst upgrades to Buy Analyst upgrades MRK to Buy, PT $143
D1 +0.2% · +5d +1.9%
› 4 waves of this story2026-08-04 Multiple sources confirm Merck's Q2 beat and raised revenue guidance, but cut profit outlook.2026-08-05 Q2 revenue $16.6B beat, Keytruda strong, FY sales guidance raised2026-08-12 Zacks notes Q2 beat and raised guidance, but earnings estimate cuts and patent risks weigh2026-08-13 Analyst upgrades MRK to Buy, PT $1432026-08-12 Insider selling
Insider selling $12.3M (2) D1 +1.9% · +5d +14.5%
2026-08-12 Analyst
Daiwa Capital upgrades to Outperform D1 +1.9% · +5d +14.5%
